Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 39.20M | $ 47.07M | $ 78.59M | $ 46.83M | $ 72.83M |
| Gross Profit | $ 39.20M | $ 47.07M | $ 78.59M | $ 46.83M | $ 72.83M |
| Operating Income | $ -349.40M | $ -261.63M | $ -165.53M | $ -161.26M | $ -100.53M |
| EBITDA | $ -303.06M | $ -216.24M | $ -143.20M | $ -151.66M | $ -97.64M |
| Net Income | $ -311.40M | $ -223.86M | $ -146.96M | $ -154.81M | $ -100.22M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 848.28M | $ 488.74M | $ 374.88M | $ 407.17M | $ 442.42M |
| Total Assets | $ 1.74B | $ 978.03M | $ 575.76M | $ 603.13M | $ 605.90M |
| Total Debt | $ 82.25M | $ 87.76M | $ 84.67M | $ 17.34M | $ 17.96M |
| Net Debt | $ -274.76M | $ -32.49M | $ -25.29M | $ -51.06M | $ -30.01M |
| Total Liabilities | $ 163.15M | $ 142.42M | $ 180.79M | $ 112.98M | $ 146.27M |
| Stockholders' Equity | $ 1.58B | $ 835.62M | $ 394.97M | $ 490.15M | $ 459.64M |
| Cash Flow | |||||
| Free Cash Flow | $ -234.34M | $ -207.34M | $ -137.31M | $ -155.92M | $ -130.54M |
| Operating Cash Flow | $ -232.89M | $ -194.50M | $ -102.83M | $ -153.09M | $ -128.95M |
| Investing Cash Flow | $ -521.06M | $ -404.08M | $ 139.89M | $ 20.52M | $ -99.83M |
| Financing Cash Flow | $ 990.71M | $ 608.85M | $ 4.19M | $ 153.00M | $ 250.28M |